E2 ModerateModerate confidencePEM not requiredCase-ControlPeer-reviewedReviewed
Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression.
Lloyd, A, Hickie, I, Hickie, C et al. · Clinical and experimental immunology · 1992 · DOI
Quick Summary
This study compared immune system function in patients with ME/CFS, people with depression, and healthy individuals. Researchers found that ME/CFS patients had weaker immune responses than both groups, suggesting their immune problems are distinct from depression-related immune changes. This indicates that ME/CFS involves direct immune system dysfunction rather than these problems simply being caused by depression.
Why It Matters
This study helped establish that ME/CFS involves genuine immune dysfunction independent of depression, validating biological disease mechanisms rather than attributing symptoms solely to psychiatric causes. Understanding that immune abnormalities are intrinsic to ME/CFS rather than secondary to depression supports the search for biological treatments and changes perceptions of disease legitimacy.
Observed Findings
- CFS patients showed impaired lymphocyte proliferation responses to PHA stimulation compared to both depression patients and healthy controls
- CFS patients demonstrated reduced or absent delayed-type hypersensitivity (DTH) skin responses versus both comparison groups
- The prevalence and magnitude of cell-mediated immune abnormalities differed between CFS and major depression groups
- Immune abnormalities in CFS were not attributable to comorbid depression alone
Inferred Conclusions
- Cell-mediated immunity disturbances in CFS have a direct biological relationship to disease etiology rather than being secondary to depression
- Immune dysfunction in CFS represents a distinct immunopathological pattern different from depression-associated immune changes
- Depression commonly present in CFS patients does not explain the observed immune abnormalities
Remaining Questions
- What specific immune mechanisms (cytokine dysregulation, specific T-cell subset abnormalities, etc.) drive the observed lymphocyte and DTH response impairments?
- Do these immune abnormalities precede symptom onset or develop secondary to illness, and do they correlate with symptom severity or type?
- What is the functional significance of reduced DTH responses and impaired PHA proliferation for actual infection control and clinical outcomes in ME/CFS?
What This Study Does Not Prove
This study does not prove that immune dysfunction causes ME/CFS symptoms—only that it is associated with the condition. It does not identify which specific immune mechanisms drive illness or explain why these abnormalities develop. The cross-sectional design cannot establish temporal relationships or determine whether immune changes precede or follow symptom onset.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Strong PhenotypingWeak Case DefinitionExploratory OnlySmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.